Investigation on Interference Signals in the Derivation of Biosignals from Wearables in Patients with Ventricular Assist Devices (SMART VADCH Trial)

Investigation on Interference Signals in the Derivation of Biosignals from Wearables in Patients with Ventricular Assist Devices (SMART VADCH Trial) - smartVADch

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036545

Enrollment

Registered

2025-07-18

Start date

2025-09-17

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50.9

Interventions

Group 1: Patients with severe heart failure and left ventricular assist devices: All patients in this study group will, in deviation from clinical routine, undergo a one-time recording of biosignals (

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Heart Failure

Exclusion criteria

Exclusion criteria: Patients without upper extremities; Patients who are not independently capable of giving consent.

Design outcomes

Primary

Measure	Time frame
Since this is a feasibility study with an observational character, investigating the occurrence of signal disturbances during the recording of biosignals via wearables in patients with heart failure, there are no classic primary or secondary endpoints such as death or re-hospitalization. The endpoint is the evaluability of the recorded biosignals (ECG and blood oxygen saturation). All data will be analyzed immediately after being recorded using both the wearable and the conventional system.	—

Measure

Time frame

Since this is a feasibility study with an observational character, investigating the occurrence of signal disturbances during the recording of biosignals via wearables in patients with heart failure, there are no classic primary or secondary endpoints such as death or re-hospitalization. The endpoint is the evaluability of the recorded biosignals (ECG and blood oxygen saturation). All data will be analyzed immediately after being recorded using both the wearable and the conventional system.

—

Secondary

Measure	Time frame
no secondary endpoints	—

Countries

Germany

Contacts

Public ContactEmanuel Heil

Deutsches Herzzentrum der Charité

emanuel.heil@dhzc-charite.de03045932462

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026